Alloplex Biotherapeutics Inc. announced the formation of a Corporate Board today: at a pivotal juncture in the organization’s development as it is poised to embark on its first-in-human clinical trial.
The inaugural members of the Board are Dr. Sung-Wuk Kim and Mr. TaeOh ‘Jared’ Chung.
Commenting on Dr. Kim’s appointment, Alloplex’s Scientific Founder and CEO, Dr. Frank Borriello MD PhD said, “My connection with Dr. Kim dates back to the early days of Alloplex when Sung made the first outside investment to Alloplex. His financial support and generous intellectual contribution has been integral to the organization’s ability to advance to the clinic in a record time of just over 5 years. There’s no doubt that he is an enthusiastic luminary in our field who is willing to tolerate risk in advancing promising assets. His exceptional track record will be a strong strategic asset to our Board.”
Dr. Kim said, “I have been impressed with scientific rigour and highly-differentiated approach of Alloplex and its SUPLEXA therapeutic cells. I am pleased to add my insights, knowledge of the Korean biotech sector and commitment to excellence to the Board to support the organization’s advancement.”
Commenting on Jared Chung’s appointment Dr. Borriello said, “Jared brings his independent perspective and proficiency in deal sourcing and fund raising to the Alloplex Board. His oversight will be immensely valuable as we execute our lead clinical cellular therapy program and seek investment and collaboration opportunities in Asia and other markets.”
“I have great confidence in the potential of Alloplex Biotherapeutics, Inc.,” Mr. Chung said, “I look forward to adding my expertise in value-creation to the Board to support Frank and his leadership team at this important time.”
Alloplex Biotherapeutics, Inc., a private biotechnology company. Alloplex has developed a highly-differentiated, non-engineered cellular therapy platform with broad anti-tumor activity. Preclinical in vitro and animal model data indicate that the platform is applicable across multiple tumor types.
Alloplex’s manufacturing planning is well-advanced. Its first in-human clinical trials are slated to commence in 1Q 2022.